On 19 November, the 7th “ESG Leading Enterprises 2025” ceremony, co-organized by Bloomberg Businessweek/Chinese Edition and Deloitte, a globally renowned accounting firm, was successfully held in Hong Kong. The event was honored to feature a keynote speech and award presentation by Mr. Joseph H.L. Chan, JP, Under Secretary for Financial Services and the Treasury of the Government of Hong Kong Special Administrative Region. Fosun International was honored as an “ESG Leading Enterprise”, in recognition of its outstanding achievements and strong market position across ESG strategy, corporate governance, social responsibility, environmental protection, information disclosure, and stakeholder engagement.

On 18 November, the Chief Executive’s Policy Unit (CEPU) of the Government of the Hong Kong Special Administrative Region, the National Academy of Economic Strategy of the Chinese Academy of Social Sciences, and the Chinese Institute of Hong Kong held the Economic Transformations in a Multipolar World - International Forum on China’s Economy and Policy 2025 at the Central Government Offices. Guo Guangchang, Chairman of Fosun International, joined the session “The New Development Landscape of Hong Kong” and delivered a speech highlighting Hong Kong’s pivotal role in advancing economic globalization and regional integration. He further emphasized that innovation is the key to shaping a vibrant future for Hong Kong.

On 13 November 2025, Hong Kong Economic Journal (HKEJ), Hong Kong’s first Chinese-language financial newspaper, hosted the “ESG & Sustainability Awards of Excellence 2025” ceremony. At the event, Fosun International received the “ESG & Corporate Sustainability Excellence Award”, recognizing its remarkable achievements and strong market standing in advancing environmental, social, and governance (ESG) practices as well as sustainability.

SHANGHAI, China – NOVEMBER 11, 2025 – Shanghai Henlius Biotech, Inc. (2696.HK) today announced the Medicines and Healthcare Products Regulatory Agency (MHRA) in the United Kingdom has granted marketing authorization for BILDYOS^® (denosumab) injection 60 mg/mL and BILPREVDA^® (denosumab) injection 120 mg/1.7 mL, biosimilars to PROLIA (denosumab) and XGEVA (denosumab), respectively, for all indications of the reference products.

On 8 November, Guo Guangchang, Chairman of Fosun International, attended the 3rd Pujiang Biopharmaceutical Original Innovation Conference 2025. During the conference, Guo Guangchang stated, “At this crucial juncture today, China’s pharmaceutical innovation is gaining increasing attention and recognition around the world. More than ever, we are convinced that original innovation is the only way forward for the industry, and open cooperation is the best way to accelerate innovation.”

On the evening of 6 November 2025, The Asset, a renowned Asian financial magazine, hosted “The Asset Corporate Sustainability Leadership Awards 2025” ceremony in Singapore. Fosun International Limited (“Fosun International” or the “Company”) (HKEX stock code: 00656) was awarded “The Asset Corporate Sustainability Leadership Awards 2025 – Gold Award” and the “Best Sustainability Team”.

On 5 November 2025, the 8th China International Import Expo (CIIE) opened at the National Exhibition and Convention Center (Shanghai). As a “full-attendance” exhibitor for eight consecutive years, Fosun, together with its overseas member companies and global partners, is showcasing a range of world-leading innovative drugs, advanced medical devices, and achievements in international collaboration at the Fosun Pharma booth in the Medical Equipment and Healthcare Products Exhibition Area. The exhibits focus on core therapeutic areas including oncology, immune-inflammatory disorders, central nervous system, and kidney diseases, highlighting holistic breakthroughs in medical technology, from diagnosis and treatment to recovery.

On October 30, 2025, the First International Jewelry Fashion Theme Month and the 2025 Shanghai Haute Couture Week officially kicked off in the Grand Yuyuan Cultural Area. As the first major event following the establishment of the Shanghai International Jewelry & Style District, this inaugural theme month not only brings a series of exciting activities but also marks a new chapter in the development of the functional district.

Hong Kong, October 28, 2025 -- Sisram Medical Ltd (the "Company" or "Sisram", 1696.HK; together with its subsidiaries collectively referred to as the "Group"), a global consumer wellness group offering Energy-Based Devices (EBD), injectables, and other complementary solutions, today announced its business update for the third quarter of 2025, highlighting solid revenue growth and accelerated momentum across core product segments and key markets.